KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zimmer Biomet Holdings (ZBH) Gains from Sales and Divestitures (2022 - 2025)

Zimmer Biomet Holdings (ZBH) has 14 years of Gains from Sales and Divestitures data on record, last reported at $683000.0 in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 68.64% year-over-year to $683000.0; the TTM value through Dec 2025 reached $683000.0, up 68.64%, while the annual FY2025 figure was $683000.0, 68.64% up from the prior year.
  • Gains from Sales and Divestitures reached $683000.0 in Q4 2025 per ZBH's latest filing, up from $405000.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $683000.0 in Q4 2025 and bottomed at $168000.0 in Q4 2022.
  • Average Gains from Sales and Divestitures over 5 years is $352000.0, with a median of $265000.0 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: decreased 29.71% in 2022, then soared 68.64% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $239000.0 in 2021, then decreased by 29.71% to $168000.0 in 2022, then surged by 57.74% to $265000.0 in 2023, then surged by 52.83% to $405000.0 in 2024, then skyrocketed by 68.64% to $683000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $683000.0 in Q4 2025, $405000.0 in Q4 2024, and $265000.0 in Q4 2023.